BDR Pharma to launch 400mg Favipiravir tablets for treating coronavirus patients in India

The company had received approval from the Drugs Controller General of India (DCGI) to manufacture Favipiravir to treat patients with mild to moderate COVID-19 symptoms under the brand name BDFAVI, according to the statement.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news